Skip to content
Peptidepedia

Tesamorelin Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

Tesamorelin combines with other peptides or compounds to enhance results, though such combinations lack formal clinical study.

Tesamorelin + Ipamorelin

This combination pairs a GHRH analog with a growth hormone-releasing peptide (GHRP). The theoretical synergy involves stimulating GH release through two complementary pathways, GHRH receptor activation and ghrelin receptor agonism, potentially producing greater GH elevation than either compound alone. Ipamorelin is the most commonly paired GHRP due to its selective GH release and minimal effect on cortisol and prolactin.

Tesamorelin + CJC-1295

Some users combine tesamorelin with CJC-1295 (another GHRH analog with extended half-life), though this approach may prove redundant given their similar mechanisms. The potential overlap in receptor targets means the additive benefit is less established than the tesamorelin + ipamorelin combination.

Tesamorelin + Lifestyle Interventions

The most evidence-supported combination involves pairing tesamorelin with structured exercise and dietary optimization. Clinical trials demonstrated that tesamorelin's benefits were additive to lifestyle modifications, making this the most pragmatic and well-supported approach for most users.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
  3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
  4. Makimura H, et al. Effects of tesamorelin on cardiometabolic risk factors in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2831-2838.
  5. Fourman LT, et al. Tesamorelin treatment for liver fat and histology in HIV-associated NAFLD. Journal of Clinical Investigation. 2019;129(11):4608-4615.
  6. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
  7. Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
  8. Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071-1091.
  9. FDA Prescribing Information for Egrifta SV (tesamorelin).
  10. World Anti-Doping Agency 2024 Prohibited List.
  11. Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
  12. Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS. 2011;25(10):1281-1288.
←Read the full Tesamorelin guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”